We are pleased to work with the Cyclowest team, Nat Lenzo and Thomas Tuchyna to bring new targeted radiotherapies to patients.
Cyclowest started to produce Zirconium-89 with a plan to obtain TGA licensing for several Zr-89 products over the next 12 months.
GlyTherix and Cyclowest have finalised a Heads of Agreement. Cyclowest will be supplying Zr-89 to facilitate joint preclinical trials with Glypican-1 agent as part of the ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals initiative at the University of Queensland by the end of 2024.
Cyclowest is now in the planning stage setting up to manufacture GMP grade labelled product by the end of 2025 from their Perth facility with roll out of this product to other Cyclowest facilities scheduled to be operational in 2026 and 2027 in the Asia Pacific region.